Home Featured Page 129

Featured

Latest

Psychedelic Funding Update: Q2 2025

Daniel Pinchbeck – From Cultural Catalyst to Capitalist Co-option: Reflections on Psychedelic Science, AI, and Idealist Monism

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Inflammation Nation: How Psychedelics Could Combat Widespread Chronic Pain

atai Life Sciences Announces First Subject Dosed in Phase 1 Trial...

MindMed Collaborators Initiate Phase 1 Comparative PK/PD Trial of R-, S-...

KetaMD Expands Access to Breakthrough Ketamine Therapy in Florida to Battle...

Interview | George Tziras, Small Pharma

Combating Suicidality: A Role for Psilocybin and Ayahuasca?

PT361 – Jason Slot, Ph.D. – Mycology and Evolutionary Genomics

Silo Pharma Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released...

Reunion Neuroscience to Participate in the Cantor Neurology & Psychiatry Conference

Silo Pharma Announces Closing of $5.75 Million Public Offering of Common...

1...128129130...292 Page 129 of 292

Psychedelic Funding Update: Q2 2025

Daniel Pinchbeck – From Cultural Catalyst to Capitalist Co-option: Reflections on...

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psychedelic Funding Update: Q2 2025

Daniel Pinchbeck – From Cultural Catalyst to Capitalist Co-option: Reflections on Psychedelic Science, AI, and Idealist Monism

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Inflammation Nation: How Psychedelics Could Combat Widespread Chronic Pain

atai Life Sciences Announces First Subject Dosed in Phase 1 Trial...

MindMed Collaborators Initiate Phase 1 Comparative PK/PD Trial of R-, S-...

KetaMD Expands Access to Breakthrough Ketamine Therapy in Florida to Battle...

Interview | George Tziras, Small Pharma

Combating Suicidality: A Role for Psilocybin and Ayahuasca?

PT361 – Jason Slot, Ph.D. – Mycology and Evolutionary Genomics

Silo Pharma Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released...

Reunion Neuroscience to Participate in the Cantor Neurology & Psychiatry Conference

Silo Pharma Announces Closing of $5.75 Million Public Offering of Common...

EDITOR PICKS

Psychedelic Funding Update: Q2 2025

Daniel Pinchbeck – From Cultural Catalyst to Capitalist Co-option: Reflections on...

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY